New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
07:16 EDTMYGNMyriad Genetics firing on all cylinders, says Cantor
After meeting with Myriad's management, Cantor thinks that the company could have significant opportunities from the diversification of its PROLARIS and Crescendo products in the near to medium term. The firm raised its price target on the stock to $42 from $39 and reiterates a Buy rating on the shares.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
09:50 EDTMYGNLeerink to hold next-generation sequencing meeting
Subscribe for More Information
07:12 EDTMYGNAmerican Congress of Obstetrics and Gynecology
2015 ACOG Annual Clinical & Scientific Meeting is being held in San Francisco on May 2-6.
May 3, 2015
17:19 EDTMYGNMyriad Genetics CEO 'actively' searching for acquisitions, WSJ says
In a Wall Street Journal interview, Myriad (MYGN) CEO Mark Capone said the company is currently developing tests for diabetes, autoimmune disorders, and neuropsychiatric conditions, while also "actively looking" for acquisitions. In a separate interview, Robert McDonough, head of Aetna's (AET) clinical policy research, remarked that Myriad should "eventually" be able to have its Vectra DA rheumatoid arthritis test covered by insurance. Reference Link
April 21, 2015
06:40 EDTMYGNStart-up to offer saliva test for breast cancer susceptibility, NY Times says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use